Aller au contenu principal
xMedica

NCT07685808ClinicalTrials.gov

Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes

A Phase 2, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Olatorepatide, a GLP-1/GIP Receptor Agonist, With Different Doses and Drug-Titration Algorithms in Participants Living With Overweight or Obesity

En recrutementAccepte des participants actuellement, selon la fiche du registre.
Contacter cette étude

En bref

This study will test an experimental drug called olatorepatide ("study drug") to determine how safe and effective this drug is compared to placebo and how easily the body can accept this drug at different doses and dosing schedules without causing…

Phase 2360 participants recherchés22 sites1 pays

Catégories

Enregistré dans 1 registre

Une même étude peut être enregistrée dans plusieurs registres. Nous l'affichons une seule fois et renvoyons vers chaque fiche que nous détenons.

Les informations de l'essai sont affichées telles que publiées par le registre, dans leur langue d'origine.

Cette étude vous intéresse ?

Se connecter ou créez un compte pour manifester votre intérêt et suivre cette étude.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2026-07-06; recorded start 2026-07-28
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 264 other studies in this databaseCounted from the lead sponsor named in the record (Regeneron Pharmaceuticals)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourSTRONG

A strong methodological design for a phase 2 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm15/15

    Active-comparator control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre0/8

    Single site, or site count not stated

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleMEDIUM

A medium-sized study: 360 participants (target), run at 22 sites.

How this score is built
  • Enrolment25/40

    360 participants (target)

  • Site count0/25

    Site count not stated in the record

  • Country count0/15

    Country count not stated in the record

  • Planned duration6/10

    Planned over about 18 months

  • Sponsor scale9/10

    Regeneron Pharmaceuticals has led 250 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Résumé

This study will test an experimental drug called olatorepatide ("study drug") to determine how safe and effective this drug is compared to placebo and how easily the body can accept this drug at different doses and dosing schedules without causing side effects, as well as how the drug is processed in the body by participants with overweight or obesity but do not have diabetes. The study is looking at: * What side effects the study drug might cause * How much study drug is in the blood at different times * How well the study drug works * What effects the study drug may have on the body at different dosing schedules * If the body makes antibodies to the study drug as this may cause the study drug to not work as well

Affections

  • Overweight or Obesity

Éligibilité

Éligibilité
SexeTous
Âges18 Years – Aucun maximum
Volontaires sainsNon

Éligibilité telle qu'elle figure dans le registre

Key Inclusion Criteria: 1. Body Mass Index (BMI) ≥30.0 kg/m\^2 to \<45.0 kg/m\^2 at screening OR 2. BMI ≥27.0 kg/m\^2 at screening with at least 1 of the following weight-related co-morbidities: Hypertension, Dyslipidemia, Prediabetes, established Obstructive Sleep Apnea (OSA), established Coronary Artery Disease (CAD), Heart failure, established cerebrovascular disease as described in the protocol Key Exclusion Criteria: 1. Previous or current diagnosis of Type 1 or Type 2 diabetes at screening 2. Change in body weight \>5 kg within approximately 3 months before screening as described in the protocol 3. Bariatric surgery, including any procedures to revise, reverse, or remove any previous bariatric surgery interventions as described in the protocol 4. History of acute or chronic pancreatitis, cholecystitis, or symptomatic gallbladder stones 5. History or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 Note: Other Protocol Defined Inclusion/ Exclusion Criteria Apply

Éligibilité en énoncés simples

Les critères de cette fiche n'ont pas encore été décomposés en énoncés distincts. Le texte du registre ci-dessus est complet et fait foi.

Conception de l'étude

Conception de l'étude
Type d'étudeInterventionnelle
PhasePhase 2
RépartitionRandomisée
Modèle d'interventionPARALLEL
Objectif principalTREATMENT
InsuQUADRUPLE (4)
Recrutement360 participants recherchés

Promoteur et collaborateurs

  • Regeneron Pharmaceuticals Promoteur

Groupes et interventions

  • Olatorepatide arm 1EXPERIMENTAL
  • Olatorepatide arm 2EXPERIMENTAL
  • Olatorepatide arm 3EXPERIMENTAL
  • Olatorepatide arm 4EXPERIMENTAL
  • Olatorepatide arm 5EXPERIMENTAL
  • Matching Placebo arm 6ACTIVE_COMPARATOR

Interventions

  • Médicament Olatorepatide

    Administered per the protocol

  • Médicament Placebo

    Administered per the protocol

Critères de jugement

  1. Critère de jugement principal

    Occurrence of Treatment-Emergent Adverse Events (TEAEs)

    Délai Up to approximately 60 weeks

  2. Critère de jugement principal

    Severity of TEAEs

    Délai Up to approximately 60 weeks

  3. Critère de jugement principal

    Percent change in body weight

    Délai From baseline to week 52

  4. Critère de jugement secondaire

    Olatorepatide concentrations

    Délai Up to approximately 60 weeks

  5. Critère de jugement secondaire

    Occurrence of Anti-Drug Antibody (ADA) to olatorepatide

    Délai Up to approximately 52 weeks

  6. Critère de jugement secondaire

    Magnitude of ADA to olatorepatide

    Délai Up to approximately 52 weeks

Dates

Dates
Date de début28 juillet 2026 (réelle)
Achèvement principal21 janvier 2028 (estimée)
Achèvement21 janvier 2028 (estimée)
Première publication6 juillet 2026 (réelle)
Dernière mise à jour18 novembre 2026
Résultats publiésNon précisé dans la fiche du registre
Statut vérifié pour la dernière foisnovembre 2026

Réelle signifie que l'événement a eu lieu. Estimée signifie que le promoteur s'y attend. Les deux ont un sens différent.

Lieux

22 sites sont en recrutement

United States

United States
ÉtablissementVilleÉtat ou régionStatut
Flourish Research, Ravenswood RheumatologyChicagoIllinoisEn recrutement
Charter Research LLC - ChicagoChicagoIllinoisEn recrutement
Alliance for Multispecialty Research (AMR) Clinical MiamiDoralFloridaEn recrutement
AMR Clinical - Fort MyersFort MyersFloridaEn recrutement
Tribe Clinical ResearchGreenvilleSouth CarolinaEn recrutement
AGA Clinical TrialsHialeahFloridaEn recrutement
Flourish Research, Nature Coast Clinical ResearchInvernessFloridaEn recrutement
Flourish Research, Jacksonville Center for Clinical ResearchJacksonvilleFloridaEn recrutement
AMR Clinical - LexingtonLexingtonKentuckyEn recrutement
K2 Medical Research Maitland LLC, Main OfficeMaitlandFloridaEn recrutement
AMR Clinical - MobileMobileAlabamaEn recrutement
NYC Research IncNew YorkNew YorkEn recrutement
AMR Clinical - Chicago Oak BrookOak BrookIllinoisEn recrutement
Velocity Clinical Research - OmahaOmahaNebraskaEn recrutement
Rochester Clinical ResearchRochesterNew YorkEn recrutement
Flourish Research, Legacy Oaks TowerSan AntonioTexasEn recrutement
The IMA Group, IMA Clinical Research St. PetersburgSt. PetersburgFloridaEn recrutement
Charter Research LLC - The VillagesThe VillagesFloridaEn recrutement
Diablo Clinical Research - Flourish ResearchWalnut CreekCaliforniaEn recrutement
Chase Medical ResearchWaterburyConnecticutEn recrutement
AMR Clinical WichitaWichitaKansasEn recrutement
Clinical Site Partners, LLC DBA Flourish ResearchWinter ParkFloridaEn recrutement

Documents de l'étude

Aucun document n'est lié dans cette fiche du registre.

Évolution au fil du temps

  1. 18 novembre 2026

    Site ajouté

    1 site added (22 total)

    2122

  2. 13 octobre 2026

    Site ajouté

    3 sites added (21 total)

    1821

  3. 29 septembre 2026

    Site ajouté

    13 sites added (18 total)

    518

  4. 20 août 2026

    Statut modifié

    Status changed from Not yet recruiting to Recruiting

    NOT_YET_RECRUITINGRECRUITING

  5. 20 août 2026

    Recrutement ouvert

    Recruitment opened

    NOT_YET_RECRUITINGRECRUITING

  6. 20 août 2026

    Site ajouté

    5 sites added (5 total)

    05